Business Context and Reporting Period
Company: MEDICINOVA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Stage: Development-stage biopharmaceutical company.
Operations: The company focuses on acquiring and developing novel small molecule therapeutics, primarily through strategic alliances with Japanese pharmaceutical companies. It has no approved products for commercial sale and has not generated product revenue. Operations are funded by equity sales and debt financing.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Revenues | $0 | $0 | N/A |
| Net Loss | $(4,795,087) | $(14,453,314) | N/A |
| Operating Expenses | $(4,943,360) | $(15,153,154) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $25,644,717 |
| Total Current Assets | N/A | N/A | $53,262,278 |
| Total Current Liabilities | N/A | N/A | $20,095,821 |
| Accumulated Deficit | N/A | N/A | $(241,435,523) |
| Shares Outstanding | N/A | N/A | 12,099,588 |
Liquidity Note: The company holds significant investments in Auction Rate Securities (ARS) totaling approximately $23.9 million. A portion of these assets is pledged as collateral for an ARS Loan payable of $17.7 million.
Material Changes vs. Prior Period
- Net Loss: The net loss for the nine months ended September 30, 2009, was $14.5 million, a decrease of approximately $6.1 million compared to the $20.5 million loss in the same period of 2008.
- Operating Expenses: Total operating expenses decreased by $3.7 million year-over-year for the nine-month period. This was primarily driven by a $3.6 million reduction in Research and Development (R&D) expenses, largely due to the completion of the Phase II clinical trial for MN-166 (Multiple Sclerosis) in the prior year.
- Investment Portfolio: The company recorded a net gain of $0.2 million on investment securities and the ARS Put for the nine months ended September 30, 2009, compared to an impairment charge of $3.3 million in the prior year period. This shift reflects changes in fair value modeling for ARS.
- Financing Activities: Net cash provided by financing activities increased significantly to $18.1 million for the nine months ended September 30, 2009, compared to less than $0.1 million in the prior year. This increase was driven by proceeds of $17.7 million from the ARS Loan.
Guidance, Outlook, and Risks
Outlook and Guidance:
- The company expects to incur substantial net losses for the foreseeable future as it continues development of prioritized candidates, specifically MN-221 (asthma/COPD) and MN-166 (Multiple Sclerosis).
- Management believes existing cash, cash equivalents, and the ARS Loan will be sufficient to fund anticipated operating requirements through at least September 30, 2010.
- Future capital requirements may necessitate additional equity or debt financing, strategic collaborations, or licensing transactions.
Material Risks and Contingencies:
- ARS Liquidity Risk: The company holds approximately $23.9 million in Auction Rate Securities (ARS). Due to market illiquidity, these securities may not be readily convertible to cash. The company relies on a loan facility from UBS secured by these assets, which can be called at the lender's discretion.
- Avigen Merger Litigation: A stockholder of Avigen, Inc. (The Pennsylvania Avenue Funds) filed a lawsuit alleging breach of fiduciary duties regarding the proposed merger between MediciNova and Avigen. MediciNova was added as a defendant in an amended complaint. Management believes it has meritorious defenses and does not expect a material adverse effect.
- Development Risk: The company has no approved products. Success depends on the clinical success of MN-221 and MN-166. Delays or failures in clinical trials could materially harm the business.
Investor Verification Checklist
- ARS Valuation and Liquidity: Verify the current fair value of the $23.9 million ARS portfolio and the terms of the $17.7 million ARS Loan, specifically the lender's ability to demand repayment.
- Merger Status: Confirm the status of the proposed merger with Avigen, Inc., including the resolution of the pending litigation filed by The Pennsylvania Avenue Funds.
- Cash Runway: Assess the accuracy of management's projection that current liquidity will sustain operations through September 30, 2010, given the high burn rate and lack of revenue.
- Clinical Trial Progress: Review enrollment and data timelines for the Phase II trial of MN-221 for acute asthma exacerbations and the Phase Ib trial for COPD.
- Accumulated Deficit: Note the accumulated deficit of $241.4 million since inception, indicating a history of significant losses.